尊敬的投資者，

我們誠摯邀請您參加藥明康德2025年度業(yè)績交流電話會，參與會議請撥打下圖電話號碼或掃碼注冊。

• 中文會議將于北京時間2026年3月24日(周二)上午7:30-8:45召開

Dear Investors,

WuXi AppTec cordially invites you to join our 2025 Annual Results Webcast. We thank you for your interest and we sincerely hope you will join us.

• English Webcast at 09:00-10:15, Mar 24 HKT (UTC+8) / 21:00-22:15, Mar 23 EST (UTC-5)

關于藥明康德

藥明康德（股票代碼：603259.SH/2359.HK）是全球醫(yī)藥及生命科學行業(yè)值得信賴的合作伙伴和重要貢獻者，致力于通過提供一體化、端到端的新藥研發(fā)和生產(chǎn)服務，推動全球醫(yī)藥健康創(chuàng)新。公司在亞洲、歐洲、北美等地均設有運營基地，依托獨特的“CRDMO”業(yè)務模式，不斷降低研發(fā)門檻，助力客戶提升研發(fā)效率，為患者帶來突破性的治療方案。目前，公司的賦能平臺正承載著來自全球30多個國家的合作伙伴的研發(fā)創(chuàng)新項目，致力于將更多新藥、好藥帶給全球病患，早日實現(xiàn)“讓天下沒有難做的藥，難治的病”的愿景。更多信息，請訪問公司網(wǎng)站：www.wuxiapptec.com

About WuXi AppTec

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time. Learn more at www.wuxiapptec.com.